Kornimate/medical-research-clean huggingface dataset:
management and outcomes of traumatic eyelid injuries in assiut university hospital

Conditions: Traumatic Eyelid Injuries

Summary: this study aim to determine the incidence of traumatic eyelid injuries presenting to a tertiary eye care center. to describe the clinical characteristics of traumatic eyelid injuries, including the etiology, location, and extent of injury. to evaluate the management approaches utilized for traumatic eyelid injuries, including surgical repair, medical therapy, and other treatments. to assess the outcomes of traumatic eyelid injuries, including functional outcomes, cosmetic results, and complication rates

vision is the most cared-for function of the human body, and the eyelids are provided to cover the eye for protection. eyelids are not only protective curtains in front of the eyes but also contribute to the shape and beauty of the face. they are complex structures designed to protect the globe from various external trauma . eyelids help to keep the corneas moist, protect against injury and excessive light, and regulate the amount of light reaching the retina. they are essential for the distribution and drainage of tears . traumatic eyelid injuries are a common occurrence and can range in severity from minor lacerations to more complex injuries involving the eyelid structures. these injuries can significantly impact a patient's visual function and cosmetic appearance. understanding the epidemiology, clinical presentation, management approaches, and outcomes of traumatic eyelid injuries is important for optimizing patient care. eyelid injuries are an important subtype of facial trauma, which necessitates the ophthalmologist being competent and fully informed . lacerated wounds of the eyelids are common features of ocular trauma and often occur in isolation without any associated intraocular injuries . eyelid lacerations can be treated using different techniques depending on their depth, width, injury mechanism, and accompanying injuries. they can be repaired with primary closure, skin flap, or skin graft. small defects limited to the skin of the eyelids can be repaired by direct closure . eyelid trauma may often appear trivial but can have profound effects on injury-associated morbidity. recovery of full eyelid function and maintenance of the lacrimal apparatus are important considerations when approaching lid trauma \[. proper information and education can help individuals to avoid eye injuries and their substantial burden .

Eligibility criteria:
inclusion criteria: * patients of all ages presenting with traumatic eyelid injuries to the study institution in either ophthalmology or emergency departments exclusion criteria: * patients presented with eyelid injuries who are: * presented late * presented after a previous intervention * known to have co-existing eyelid pathology (as tumors, infections, congenital abnormalities) * patients with incomplete medical records or loss to follow-up
hypotensive anesthesia for orthognathic surgery

Conditions: Hypotensive Anesthesia; Orthognathic Surgery

Summary: the overall objective of this double blinded, randomized controlled trial (rct) is to compare specific outcomes of three medications (dexmedetomidine, nicardipine, and labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. the outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events. the specific objectives of this study are to compare: 1. dexmedetomidine, nicardipine, and labetalol's effect on the quality of the surgical field. (primary outcome) 2. dexmedetomidine, nicardipine, and labetalol's effect on estimated blood loss. 3. dexmedetomidine, nicardipine, and labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate. 4. dexmedetomidine, nicardipine, and labetalol's effect on operation time. 5. dexmedetomidine, nicardipine, and labetalol's effect on adverse events. the investigators will evaluate healthy adult male and female patients who require jaw surgery at boston medical center. the anticipated 90 participants will be randomized into three groups: ) a labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) a nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) a dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine. the time it will take for each individual participant ranges from 1-3 months. this time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.


Eligibility criteria:
inclusion criteria: * adult patients undergoing orthognathic surgery \[le fort i, surgically assisted rapid palatal expansion (sarpe), bilateral sagittal split osteotomy (bsso), or a combination these surgeries\] at boston medical center with dr. mehra * healthy, american society of anesthesiologists (asa) physical status classification system i or ii exclusion criteria: * patients on a home beta blocker * patients on home calcium channel blocker * patients on home alpha 2 agonists * patients with an allergy to one or more of the intervention medications * does not speak english * pregnant patients (this is assessed day of surgery per standard care with a urine pregnancy test) * patients who have contraindications to induced hypotensive anesthesia

Keywords: dexmedetomidine nicardipine labetalol surgeon visibility blood loss hemodynamic parameters operation time
mobile technology for reducing and preventing adolescent suicide

Conditions: Suicide, Attempted; Suicidal Ideation

Summary: this single-group open-label trial will evaluate the feasibility and preliminary efficacy of a suicide prevention mobile application when used as an adjunct to usual care in adolescents.

this study will enroll 20 adolescent (age 13-17) inpatients at elevated risk for suicide. participants will download the app onto their phones during their inpatient stay and will complete a single therapy session involving psychoeducation and crisis response planning. participants will be encouraged to use the app on their own in addition to their usual outpatient services to learn and practice suicide prevention skills. participants and their parents will be interviewed 1, 4, 8, 12, and 16 weeks after discharge.

Eligibility criteria:
inclusion criteria: * inpatient psychiatric patients who have attempted suicide (lifetime) or have documented suicide ideation and a plan to harm themselves at admission * understand written and spoken english * own an iphone with ios 11 or higher, or android with os 8.1 or higher * willing and able to complete enrollment procedures * parent/guardian (and youth) able to understand the nature of the study and provide written informed consent (assent for youth) * willing to agree to release of information to their parent/guardian and providers when clinically indicated. * discharge plan includes aftercare within the hartford healthcare system (to facilitate coordination of care during follow up) exclusion criteria: * patients with active psychosis * patients experiencing substance withdrawal * currently enrolled in other treatment studies for the symptoms and behaviors targeted * patient unwilling or unable to wear mask during in-person study procedures * patients who, in the judgment of the investigator, would have an unfavorable risk/benefit profile with respect to the smartphone app. * any other psychiatric or medical condition (e.g., intellectual disability) or custody arrangement that in the investigator's opinion would preclude informed consent/assent or participation in the trial.
scalp psoriasis treatment with a fiber optic comb

Conditions: Psoriasis

Summary: this study will test the safety and effectiveness of a novel fiber optic device for treating scalp psoriasis with ultraviolet (uv-b) light. a effective treatment is not currently available for people with scalp psoriasis. present methods for treating psoriasis with uv-b light cannot be used for the scalp because hair is usually blocking the light from reaching the affected skin. our method overcomes this problem with the use of a comb that has optical fibers to deliver light directly to the skin. we will evaluate this device in a clinical setting and will use the results to tailor the design of the comb before producing it in large quantities.

scalp psoriasis can be treated with a novel fiber optic delivery system that irradiates the psoriatic scalp of patients with uv-b light via an optical fiber comb. current methods for treatment of psoriasis with light are not applicable to the scalp because hair is usually blocking the light from reaching the affected skin. our method overcomes this problem with the use of a comb that has optical fibers to deliver light directly to the skin. we have developed a uv-b light source and a fiber optic comb for use in clinics and doctors' offices. we will evaluate this device in a clinical setting. the results of this trial will provide data about the effectiveness of the device. we will use these results to tailor the design before it is ready for volume production. if successful, the uv-b light source and fiber optic comb will provide treatment to people affected with scalp psoriasis. at present, these people do not have any effective treatment available to them.

Eligibility criteria:
inclusion criteria: * subjects of either sex and any race or ethnic background with chronic, stable, bilateral psoriasis of the scalp. exclusion criteria: * subjects who are currently taking systemic medications for psoriasis (e.g., methotrexate, retinoids). * subjects who are currently using or have used topical medications other than emollients in the past 6 weeks on their scalp. * patients with pustular psoriasis, known photosensitivity disorders, lupus erythematosus, or unstable major illnesses preventing participation in the study.

Keywords: phototherapy psoriasis scalp psoriasis fiber optic light comb uv source
telmisartan (micardis) and ramipril (altace) - factorial design study for the treatment of hypertension

Conditions: Hypertension

Summary: to identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with stage i or ii hypertension.


Eligibility criteria:
inclusion criteria: * male and female patients \>=18 years of age with stage i or ii hypertension defined as: * a mean seated cuff diastolic blood pressure \>=95 and \<=119 mmhg main exclusion criteria: * pregnant * breast-feeding * unwilling to use birth control during the study * secondary hypertension * sbp\>=180 mmhg * dbp\>=120 mmhg * severe renal dysfunction * hepatic insufficiency * stroke within the last 6 months * myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months * unstable or uncontrolled diabetes * history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.
retrospective observational study investigating fluciclovine (18f) (facbc)

Conditions: Prostatic Neoplasms

Summary: this retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of fluciclovine 18f employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.

this study will collect clinical data from consenting patients (unless a hipaa waiver or equivalent was granted) who received the pet radiotracer fluciclovine 18f (facbc) (a synthetic amino acid analog) for imaging of patients with various cancers at participating sites in the us and europe. data collection will cover baseline medical history and medications in all patients. the result of pet radiotracer and other imaging findings, and reports of histopathology from biopsied tissue (where available) and in a time window relevant to the use of pet imaging in the diagnosis of primary/recurrent prostate cancer will be recorded. in all subjects, with regards to safety monitoring, available data for physical examination, vital signs and laboratory test results will be collected from 28 days prior to and out to a 35 day window after fluciclovine 18f (facbc) administration. the major goals of the investigation are to consolidate the safety profile of fluciclovine 18f (facbc), to evaluate its use in the detection of local and extraprostatic recurrence of prostate cancer and to evaluate its ability to detect malignancy in patients undergoing screening for primary prostate cancer.

Eligibility criteria:
inclusion criteria: * patient managed by a site at which ethical committee approval for retrospective data collection under this protocol has been received * patient has received at least one injection of fluciclovine (18f) for the detection of a malignant tumour at any location exclusion criteria: * subjects will be excluded from the analyses if any of the following criteria are met: * patients participating in clinical trials or open access programmes at countries or sites not participating in this study. * patients managed at sites without ethical committee approval for retrospective data collection under this protocol.

Keywords: observational study
concordance between the foot-to-apex systolic interval and the auscultatory method for measurement of brachial systolic pressure in patients with severe renal failure

Conditions: Renal Insufficiency

Summary: the investigators hypothesize that the systolic foot-to-apex time interval (sfati) method will be accurate for measurement of systolic blood pressure with marked arterial stiffness as seen in patients with severe renal impairment. also that the presence of arterial calcifications only changes the agreement between the sfati method and the reference method (auscultatory method) if the calcifications are very severe.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * patient under consultation in the nephrology for severe renal impairment (defined by a glomerular filtration rate \<30 ml / min, assessment within previous 3 months) exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * patient is pregnant or breastfeeding
intramuscular injections of degarelix administered in 1-month dosing regimens in patients with prostate cancer

Conditions: Prostate Cancer

Summary: intramuscular injections of degarelix administered in 1-month dosing regimens in patients with prostate cancer.


Eligibility criteria:
inclusion criteria: * has a histologically confirmed adenocarcinoma of the prostate, for which endocrine therapy is indicated * has a current tumour, nodule and metastasis (tnm) staging within 12 weeks prior to treatment start and, if clinically indicated a bone scan * has a psa level meeting one of these criteria: 1. for treatment-naïve patients: screening psa level should be ≥2 ng/ml. 2. for patients with recurrence after radical prostatectomy: patients should have a serum psa increase of ≥0.2 ng/ml from the previous test on two consecutive measurements 3. for patients with recurrence after radiotherapy or cryotherapy: patients should have a serum psa (two measurements) to be \>2 ng/ml higher than a previously confirmed psa nadir * has a screening serum testosterone level above the lower limit of normal range in an elderly male population, globally defined as \>150 ng/dl * has an eastern cooperative oncology group score of ≤2 * has a life expectancy of at least one year exclusion criteria: * has had previous or is currently under hormonal management of prostate cancer * is considered to be a candidate for curative therapy i.e. radical prostatectomy or radiotherapy during the trial period * has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy * has a marked baseline prolongation of qt/qtcf interval (e.g. repeated demonstration of a qtcf interval \>450 ms) * has a history of risk factors for torsade de pointes ventricular arrhythmias (e.g. heart failure, hypokalemia, or family history of long qt syndrome) * has a previous history or presence of another malignancy, other than prostate * currently receiving chronic treatment with intramuscular medication injected into the ventrogluteal or dorsogluteal muscle * has received an investigational drug within the last 28 days preceding the screening visit or longer if considered to possibly influence the outcome of the current trial
breast cancer proteomics and molecular heterogeneity

Conditions: Primary Breast Cancer; Recurrent/Metastatic Breast Cancer

Summary: primary objective: the primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of s100 protein and the estrogen receptor (er), progesterone receptor (pr) and epidermal growth factor receptor 2 (her2) genes secondary objective: * to expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * to relate proteomic findings to survival data * to identify potential serum markers of breast cancer progression

this is a translational study. patient will undergo standard treatment and tissue and blood samples will be taken at various time points: tissue: fresh frozen (ff) and formalin fixed paraffin embedded tissue (ffpe) will be collected at time of surgery/biopsy of a primary or a recurrent/metastatic tumour tissue. blood: two types of study bloods (non-heparinised and ethylenediaminetetraacetic acid (edta)) will be taken pre-neoadjuvant treatment (if applicable), pre- and post-operatively of primary and recurrent/ metastatic breast cancer (if recurrent/metastatic diagnosis and no biopsy/surgery required then study bloods will be taken prior to starting treatment). additional blood samples will be taken annually at follow-up visits for 5 years from primary cases and for up to 2 years from recurrent/metastatic cases. non-heparinised blood will be processed to serum. clinical data will be collected at all times of biological sampling.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue or -patients with suspected or confirmed recurrent or metastatic breast cancer (patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue or -patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue 2. patients receiving neoadjuvant treatment are also eligible (if applicable) 3. patients have to be ≥ 18 years of age 4. patients must be able to give informed consent
assesment of vitamin b6 level in patients with major depressive disorder

Conditions: Vitamin b6 Level & Depression

Summary: estimation of vitamin b 6 levels in diagnosed major depressive disorder patients and their relation to the severity of the disease

major depressive disorder (mdd) is a chronic health condition with significant consequences for health care costs, disability, quality of life, medical morbidity, and mortality. the world health organization (who) has considered depression as the leading cause of disability, a major contributor to overall global burden of disease . the core symptoms of depression are low mood and loss of interest or enjoyment in usually pleasurable activities. associated symptoms include disturbances to sleep and appetite, reduced energy and concentration, negative thoughts of guilt or worthlessness and suicidal ideation. the international statistical classification of diseases \& related health problems (icd-10) states that for a diagnosis of depression at least five symptoms need to be present, including at least one of the core symptoms, at an intensity that causes functional impairment and for a minimum duration of 2 weeks. vitamin b6 (pyridoxine) is a water-soluble compound that comprises three different pyridine derivatives, pyridoxine, pyridoxal, and pyridoxamine, of which plp(pyridoxal phosphate) is the biologically most active form. the coenzyme plp is an essential cofactor for amino acid decarboxylases involved in the synthesis of neurotransmitters implicated in depression, including dopamine, norepinephrine ,serotonin or 5-hydroxytryptamine (5-ht), and γ-amino butyric acid (gaba). it prevents the accumulation of neurotoxic intermediates produced during tryptophan metabolism, acting as a cofactor in the metabolism of tryptophan through the kynurenine aminotransferase and kynureninase enzymes. inadequate intake of vitamin b6 has recently been linked to an increased risk of anxiety and depression in a cross-sectional study of over 3,000 individuals.

Eligibility criteria:
inclusion criteria: * all participants must fulfill the following inclusion criteria; 1. patients diagnosed newly as major depressive disorder according to dsm-5( diagnostic and statistical manual ) and (apa 2013) . 2. aged at least 18 years of both sex . 3. able to give informed consent . exclusion criteria: 1. patients have comorbidity with other psychiatric disorders . 2. patients have chronic medical conditions , chronic debilitating or nutritional disorders . 3. for control , patients with any psychiatric disorders .
occludin and zonulin in attention-deficit/hyperactivity disorder

Conditions: Attention-deficit/Hyperactivity Disorder

Summary: the association between levels of zonulin and occludin and behavioral/emotional problems in children with adhd are investigated.

inclusion criteria for the adhd group are (a) newly diagnosed adhd (b) no prior psychotropic treatment for adhd or any psychiatric disorder (c) age 6-12 years. exclusion criteria were: (a) history of history of inflammatory/noninflammatory, metabolic, or autoimmune disease (b) any special diet history within the past year (c) use of corticosteroids or regular intake of medication in the last 6 months, (d) body mass index (bmi) \[kg/m2\] \> 30), and (e) cognitive deficits by developmental history.

Eligibility criteria:
inclusion criteria: * (a) newly diagnosed adhd * (b) no prior psychotropic treatment for adhd or any psychiatric disorder * (c) age 6-12 years. exclusion criteria: * (a) history of history of inflammatory/noninflammatory, metabolic, or autoimmune disease * (b) any special diet history within the past year * (c) use of corticosteroids or regular intake of medication in the last 6 months, * (d) body mass index (bmi) \[kg/m2\] \> 30), * (e) cognitive deficits by developmental history